Free Trial
NASDAQ:VERA

Vera Therapeutics Q2 2025 Earnings Report

Vera Therapeutics logo
$19.79 +0.07 (+0.35%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$19.80 +0.01 (+0.03%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.82
Beat/Miss
N/A
One Year Ago EPS
N/A

Vera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vera Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Vera Therapeutics Earnings Headlines

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
Lifesci Capital Issues Negative Forecast for VERA Earnings
HC Wainwright Analysts Lower Earnings Estimates for VERA
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA), a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

View Vera Therapeutics Profile

More Earnings Resources from MarketBeat